[Canine leishmaniosis in Central Europe: retrospective survey and serological study of imported and travelling dogs].
Canine leishmaniosis is a common parasitic disease in Central Europe affecting dogs imported or returning from endemic countries around the Mediterranean basin. Through an internet discussion forum owners of dogs with suspected or proven leishmaniosis living in Central Europe (D, A, CH), were questioned about the dog's history. Additionally, serologic examinations of the dogs for anti-Leishmania antibodies (ELISA using antigen of promastigote stages) were offered to the participants. From February to October 2003, 291 dogs imported or returning from Southern Europe (Spain, Italy, Greece, Turkey, France, Malta, Portugal and others) were analysed. Serologically, 111 dogs (38%) were classified positive; 103 being imported and eight travelling dogs. The majority of seropositive dogs originated from Spain (67%). No significant correlation could be established between race, sex and age and the incidence of the disease. The clinical symptoms in the seropositive dogs varied widely and ranged from mild general symptoms to visceral manifestations with chronic renal failure. Skin disorders were found in 78% of the seropositive, symptomatic animals. In the country of origin or after import or return, 174 out of 291 dogs (60%) had been tested for the presence of anti-Leishmania antibodies by different immunofluorescence antibody tests (IFAT). Discrepancies between the ELISA and the various IFATs used were noted in 55 cases (32%), especially in cases of low IFAT titers. Most of the seropositive dogs (80%) had been treated against leishmaniosis. In 91% of these cases, Allopurinol as monotherapy or in combination with Glucantime had been used. For diagnostics and therapy, dog owners had spent an average of 1,100 euros (median 900 euros, maximum 5,800 euros).
Mettler
Maik
M
Institut für Parasitologie, Universität Zürich, Zürich, Schweiz.
Grimm
Felix
F
Naucke
Torsten J
TJ
Maasjost
Christiane
C
Deplazes
Peter
P
D000818:Animals; D000913:Antibodies, Protozoan / Q000097:blood*; D003365:Costs and Cost Analysis; D004283:Dog Diseases / Q000175:diagnosis / Q000188:drug therapy / Q000191:economics / Q000453:epidemiology*; D004285:Dogs; D019353:Endemic Diseases / Q000191:economics / Q000706:statistics & numerical data / Q000662:veterinary*; D005060:Europe / Q000453:epidemiology; D005260:Female; D007891:Leishmania / Q000276:immunology*; D007896:Leishmaniasis / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology / Q000662:veterinary*; D008297:Male; D012189:Retrospective Studies; D016036:Seroepidemiologic Studies; D014195:Travel
D000913:Antibodies, Protozoan